News & Events
Dr. Stephan Morris, Insight Genetics’ Scientific Founder and Chief Scientific Officer, presented at the San Francisco State University Biology Conference, “Personalized Medicine 8.0: Genetic Screening Symposium & Predictive Medicine” on May 28, 2015. The Symposium brought together leaders in the Precision Medicine field, discussing topics including the Changing Landscape of Oncology, Consumer Genetics in the Age of Predictive Medicine, the Impact of Genomics in Reproductive Medicine, and Genetic Screening in Neurodegenerative and Psychiatric Diseases.
Dr. Morris spoke about the discovery of ALK in his laboratory at St. Jude Children’s Research Hospital in the mid-1990s and how ALK was shown to be an oncogenic driver in Non-Small Cell Lung Cancer (NSCLC) and other cancers. Currently, there are two ALK inhibitors approved by the US FDA and close to ten next-generation ALK inhibitor compounds in development for the treatment of patients with ALK-driven NSCLC. Dr. Morris also discussed his work that helped lead to the development of the ALK break-apart FISH assay, which was co-approved as the companion diagnostic test together with the two FDA-approved ALK inhibitors. The presentation also included a discussion about the various ALK diagnostics commercially available and in development, comparing and contrasting the capabilities of the different assays.